These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32170782)

  • 21. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.
    Bonovas S; Lytras T; Nikolopoulos G; Peyrin-Biroulet L; Danese S
    Aliment Pharmacol Ther; 2018 Feb; 47(4):454-465. PubMed ID: 29205421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment with biologic therapies and the risk of cancer in patients with IBD.
    Biancone L; Calabrese E; Petruzziello C; Pallone F
    Nat Clin Pract Gastroenterol Hepatol; 2007 Feb; 4(2):78-91. PubMed ID: 17268543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients.
    Khan N; Vallarino C; Lissoos T; Darr U; Luo M
    Drugs Aging; 2017 Nov; 34(11):859-868. PubMed ID: 29170864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
    Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
    Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease.
    Hindryckx P; Novak G; Bonovas S; Peyrin-Biroulet L; Danese S
    Clin Pharmacol Ther; 2017 Oct; 102(4):633-641. PubMed ID: 28699217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of infections with biological agents.
    Kopylov U; Afif W
    Gastroenterol Clin North Am; 2014 Sep; 43(3):509-24. PubMed ID: 25110256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of Postoperative Infectious Complications From Medical Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Law CCY; Koh D; Bao Y; Jairath V; Narula N
    Inflamm Bowel Dis; 2020 Nov; 26(12):1796-1807. PubMed ID: 32047894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Malignancy risk in individuals with familial adenomatous polyposis receiving biologics and immunomodulators.
    Faisal MS; Burke CA; Achkar JP; Click B; O'Malley M; LaGuardia L; Milicia S; Leach B; Liska D; Church J; Kalady M; Mankaney G
    Fam Cancer; 2022 Apr; 21(2):189-195. PubMed ID: 33822277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.
    Kirchgesner J; Lemaitre M; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
    Gastroenterology; 2018 Aug; 155(2):337-346.e10. PubMed ID: 29655835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonadherence to Biologic Therapies in Inflammatory Bowel Disease.
    Wentworth BJ; Buerlein RCD; Tuskey AG; Overby MA; Smolkin ME; Behm BW
    Inflamm Bowel Dis; 2018 Aug; 24(9):2053-2061. PubMed ID: 29668917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease: a meta-analysis.
    Lapumnuaypol K; Kanjanahattakij N; Pisarcik D; Thongprayoon C; Wijarnpreecha K; Cheungpasitporn W
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):854-860. PubMed ID: 29697458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: A systematic review.
    Khan S; Rupniewska E; Neighbors M; Singer D; Chiarappa J; Obando C
    J Clin Pharm Ther; 2019 Aug; 44(4):495-507. PubMed ID: 30873648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing the safety of biologic therapy for IBD.
    de Silva S; Devlin S; Panaccione R
    Nat Rev Gastroenterol Hepatol; 2010 Feb; 7(2):93-101. PubMed ID: 20134491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pregnant women with IBD are more likely to be adherent to biologic therapies than other medications.
    Lee S; Seow CH; Adhikari K; Metcalfe A
    Aliment Pharmacol Ther; 2020 Mar; 51(5):544-552. PubMed ID: 31797416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging biologics in inflammatory bowel disease.
    Chan HC; Ng SC
    J Gastroenterol; 2017 Feb; 52(2):141-150. PubMed ID: 27832357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden.
    Everhov ÅH; Halfvarson J; Myrelid P; Sachs MC; Nordenvall C; Söderling J; Ekbom A; Neovius M; Ludvigsson JF; Askling J; Olén O
    Gastroenterology; 2018 Feb; 154(3):518-528.e15. PubMed ID: 29102619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does a personal or family history of malignancy preclude the use of immunomodulators and biologics in IBD.
    Kalman RS; Hartshorn K; Farraye FA
    Inflamm Bowel Dis; 2015 Feb; 21(2):428-35. PubMed ID: 25251059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Croatian consensus on the treatment of inflammatory bowel diseases with biologic therapy].
    Vucelić B; Cuković-Cavka S; Banić M; Bilić A; Borzan V; Duvnjak M; Katicić M; Kolacek S; Krznarić Z; Kujundzić M; Marusić M; Mihaljević S; Mijandrusić BS; Persić M; Simunić M; Skurla B; Stimac D; Tonkić A; Troskot B
    Acta Med Croatica; 2013 Apr; 67(2):75-87. PubMed ID: 24471291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Corticosteroids and Thiopurines, But Not Tumor Necrosis Factor Antagonists, are Associated With Cytomegalovirus Reactivation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Shukla T; Singh S; Tandon P; McCurdy JD
    J Clin Gastroenterol; 2017; 51(5):394-401. PubMed ID: 27875356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents.
    Papaefthymiou A; Potamianos S; Goulas A; Doulberis M; Kountouras J; Polyzos SA
    J Crohns Colitis; 2022 Jun; 16(5):852-862. PubMed ID: 34972203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.